Share chart Zymeworks Inc.
Extended chart
Simple chart
About Zymeworks Inc.
Zymeworks Inc., биофармацевтическая компания, работающая на клинической стадии, занимается открытием, разработкой и коммерциализацией биотерапевтических средств для лечения рака. more details| IPO date | 2017-04-28 |
|---|---|
| ISIN | CA98985W1023 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | http://www.zymeworks.com |
| Цена ао | 12.8 |
| Change price per day: | +12.61% (9.44) |
|---|---|
| Change price per week: | -2.92% (10.95) |
| Change price per month: | -13.44% (12.28) |
| Change price per 3 month: | -19.59% (13.22) |
| Change price per half year: | -20.08% (13.3) |
| Change price per year: | +13.57% (9.36) |
| Change price per 3 year: | +98.69% (5.35) |
| Change price per 5 year: | -68.43% (33.67) |
| Change price per year to date: | -21.72% (13.58) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| EcoR1 Capital, LLC | 13437473 | 21.33 |
| BVF Inc. | 5870000 | 9.32 |
| Redmile Group, LLC | 5790230 | 9.19 |
| Morgan Stanley | 4861286 | 7.72 |
| Blackrock Inc. | 3923328 | 6.23 |
| Rubric Capital Management LP | 3475384 | 5.52 |
| Vanguard Group Inc | 2394712 | 3.8 |
| Credit Suisse Ag/ | 2303621 | 3.66 |
| Bnp Paribas Asset Management Holding S.a. | 1771776 | 2.81 |
| Farallon Capital Management Llc | 1756000 | 2.79 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Future Tech ETF | 0.0914 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.0914 | 618.5 | 0.8416 |
| iShares Morningstar Small-Cap Value ETF | 0.02408 | 197.28 | 2.50476 |
| iShares Morningstar Small-Cap ETF | 0.01165 | 391.25 | 1.60498 |
| 0.05 | 408.34 | 1.45 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Paul Moore Ph.D. | Chief Scientific Officer | 872.67k | 1968 (57 years) |
| Mr. Kenneth H. Galbraith C.A. | Chairman of the Board & CEO | 1963 (62 years) | |
| Ms. Leone D. Patterson M.B.A. | CFO, EVP & Chief Business Officer | 1962 (63 years) | |
| Mr. Mark Hollywood | Executive VP and Head of Technical & Manufacturing Operations | 1970 (55 years) | |
| Mr. Daniel Dex J.D., Ph.D. | Senior VP, Corporate Secretary & General Counsel | ||
| Diana Papove | Senior Manager of Corporate Communications | ||
| Dr. Lindsey Foulkes B.Sc., Ph.D. | Vice President of Corporate Development | ||
| Ms. Laura O'Connor | Vice President of Human Resources & DEI | ||
| Dr. Jeffrey Smith M.D. | Executive VP & Chief Medical Officer | ||
| Dr. Josemund Menezes MBBS | Managing Director of Early-Stage Development for Asia Pacific |
Address: Canada, Vancouver, 1385 West 8th Avenue - open in Google maps, open in Yandex maps
Website: http://www.zymeworks.com
Website: http://www.zymeworks.com
